other material
confidence high
sentiment positive
materiality 0.75
Aurinia receives key patent allowance for LUPKYNIS dosing and PTAB terminates IPR challenge
Aurinia Pharmaceuticals Inc.
- USPTO allowed patent application 17/713,140 for LUPKYNIS dosing with eGFR, extending protection to 2037.
- PTAB terminated Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036 (Orange Book-listed).
- New patent supplements existing method-of-use patent; Aurinia intends to list it in Orange Book when issued.